Claritev Corporation (CTEV)
| Market Cap | 279.92M -24.6% |
| Revenue (ttm) | 978.76M +5.5% |
| Net Income | -286.52M |
| EPS | -17.33 |
| Shares Out | 17.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,045 |
| Open | 12.91 |
| Previous Close | 13.87 |
| Day's Range | 11.50 - 18.40 |
| 52-Week Range | 11.50 - 74.07 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 43.60 (+165.53%) |
| Earnings Date | May 7, 2026 |
About CTEV
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical neg... [Read more]
Financial Performance
In 2025, Claritev's revenue was $965.41 million, an increase of 3.74% compared to the previous year's $930.62 million. Losses were -$284.28 million, -82.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CTEV stock is "Buy." The 12-month stock price target is $43.6, which is an increase of 165.53% from the latest price.
News
Claritev says cooperating with DOJ, not informed of being target
Claritev (CTEV) disclosed that nn article published on Thursday, May 14, 2026 alleges that “DOJ launches criminal antitrust probe into Claritev.” In August of 2024, the company said it received…
Claritev jumps after saying DOJ has not informed company of being target
The shares are up 20%, or $2.78, to $16.65 in midday trading.
Claritev probed by DOJ’s antitrust division, Capitol Forum reports
The Justice Department’s antitrust division has launched a criminal price-fixing investigation into Claritev (CTEV), a pricing intermediary that major health insurers use to set reimbursement rates fo...
Claritev rallies after commenting on last week’s Capitol Forum report
12:29 EDT Claritev (CTEV) rallies after commenting on last week’s Capitol Forum report
Claritev discloses criminal antitrust probe by Justice Department
12:24 EDT Claritev (CTEV) discloses criminal antitrust probe by Justice Department
Claritev Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a strong growth trajectory, with record Q1 bookings, robust pipeline expansion, and ambitious revenue and EBITDA targets through 2030. Strategic investments in technology and AI, along with deep client relationships, are expected to drive continued success.
Claritev price target raised to $40 from $21 at Citi
In a sector note on U.S. HealthTech & Distribution, Citi raised the firm’s price target on Claritev (CTEV) to $40 from $21 and keeps a Buy rating on the shares,…
Claritev launches PHCS Novera solution
Claritev (CTEV) Corporation announced the launch of PHCS Novera, a primary network solution designed to help deliver flexible, competitive options. With nearly two-thirds of covered workers enrolled i...
Claritev Launches PHCS Novera to Give TPAs More Control Over Network Design Amid Rising Healthcare Costs
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #CostContainment--As healthcare costs accelerate and employers demand more control over network strategy, Claritev Corporation (NYSE: CTEV), a healthcare technol...
Claritev Corporation Announces Participation in BofA Securities Global Health Care Conference 2026
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev Earnings Call Transcript: Q1 2026
Q1 saw revenue and EBITDA exceed expectations, driven by strong core and expansion performance, record ACV bookings, and operational efficiencies from AI. Raised revenue guidance and maintained EBITDA outlook, with continued investment in growth and deleveraging focus.
Claritev reports Q1 EPS ($4.41) vs. ($4.38) last year
Reports Q1 revenue $244.7M, consensus $238.59M. “Claritev (CTEV) kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations…
Claritev narrows FY26 revenue view to $985M-$1B from $980M-$1B
FY26 revenue consensus $990.02M. Backs FY26 adjusted EBITDA view $605M-$615M and CapEx view $160M-$170M.
Claritev Corporation Reports First Quarter 2026 Results
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev Chief AI Officer Fernando Schwartz Named to DataIQ 100 for Advancing AI-Driven Healthcare Performance
MCLEAN, Va.--(BUSINESS WIRE)--Claritev, a healthcare technology, data, and insights company, today announced that Fernando Schwartz, Ph.D., Senior Vice President and Chief AI Officer, has been named t...
Claritev Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and incentive plan amendments. All proposals passed with no questions from stockholders, and final results will be filed with the SEC.
Claritev initiated with an Overweight at Barclays
Barclays initiated coverage of Claritev (CTEV) with an Overweight rating and $28 price target With the shares down 70% from the peak in September, Claritev’s risk/reward skews positive, the analyst…
Claritev Corporation Announces First Quarter 2026 Earnings Conference Call
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transpar...
Claritev Cares Opens Rural Health Grants, Continuing Three Decades of Investment in Underserved Communities
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more transparent and aff...
Claritev Transcript: Investor Day 2026
The company outlined a long-term growth strategy centered on transparency, technology, and diversification, highlighted by major new contracts and a robust product roadmap. Investments in AI and cloud infrastructure are driving operational efficiency and product innovation, while financial guidance targets steady revenue growth, margin expansion, and strong free cash flow by 2030.
Claritev Transcript: Status update
Growth momentum continues with record bookings, strong pipeline, and reduced client concentration. AI integration and proprietary assets drive competitive advantage, while disciplined capital allocation supports tech transformation and expansion into new markets.
Claritev Corporation Announces Participation in Upcoming Events
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev Corporation To Host 2026 Investor Day
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev price target lowered to $21 from $63 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on Claritev (CTEV) to $21 from $63 and keeps a Buy rating on the shares.
Claritev Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Claritev Corporation (NYSE: CTEV). The investigation focuses on Claritev's...